Healthcare Equities

The companies that provide, support or coordinate medical goods and services. This sector spans a broad range of activities – including the development and manufacture of medical equipment, pharmaceuticals and other treatments. Activities range from research to manufacturing, administration, insurance and facilities management. Our Healthcare research includes healthcare services, healthcare information technology (IT), medical devices, biotechnology, biopharmaceuticals and specialty pharmaceuticals.

Actinogen Medical (ACW)

Latest price

AUD0.08

— 0.00 (0.00)

As at 26/07/2024

Market capitalisation: AUD211m

View equity

Flash note

Healthcare

28.06.24

Actinogen Medical — Publication of XanADu biomarker analysis

Update

Healthcare

15.05.24

Actinogen Medical — Funding in place through key catalysts

Flash note

Healthcare

16.04.24

NZD3.00

▾ −0.02 (−0.66)

As at 26/07/2024

Market capitalisation: NZD315m

View equity

Flash note

Healthcare

10.07.24

AFT Pharmaceuticals — Continued execution of footprint expansion

Update

Healthcare

23.05.24

AFT Pharmaceuticals — Growth underpinned by international momentum

Flash note

Healthcare

02.05.24

AUD0.31

▾ 0.01 (3.33)

As at 26/07/2024

Market capitalisation: —

View equity

Update

Healthcare

04.11.19

MGC Pharmaceuticals — Rapid prescription growth in Australia and the UK

Update

Healthcare

10.07.19

MGC Pharmaceuticals — Initial CannEpil purchase orders received

Update

Healthcare

01.03.19

CHF39.30

▾ −0.05 (−0.13)

As at 26/07/2024

Market capitalisation: CHF518m

View equity

Flash note

Healthcare

21.06.24

Basilea Pharmaceutica — Final oncology asset (lisavanbulin) divested

Flash note

Healthcare

17.05.24

Basilea Pharmaceutica — Cresemba milestone payments continue to roll in

Update

Healthcare

22.04.24

SEK3.80

▾ −0.04 (−1.04)

As at 26/07/2024

Market capitalisation: SEK699m

View equity

Flash note

Healthcare

19.04.23

Cantargia — Encouraging data for nadunolimab in CANFOUR

Flash note

Healthcare

14.03.23

Cantargia — First patient treated in Phase II part of TRIFOUR

Update

Healthcare

27.02.23

SEK6.10

▾ −0.15 (−2.40)

As at 26/07/2024

Market capitalisation: SEK1,714m

View equity

Flash note

Healthcare

02.07.24

Cereno Scientific — CS1 Phase II results inbound; first dose of CS014

Update

Healthcare

21.06.24

Cereno Scientific — CS014 (second asset) crosses into the clinic

Update

Healthcare

24.05.24

SEK0.94

▾ −0.01 (−1.05)

As at 26/07/2024

Market capitalisation: SEK67m

View equity

thematic

Healthcare

04.01.24

Outlook for 2024: Life sciences – where has the conviction gone?

Update

Healthcare

02.06.23

Chosa Oncology — Making headway in precision oncology

Update

Healthcare

28.02.22

GBP0.31

— 0.00 (0.00)

As at 26/07/2024

Market capitalisation: GBP113m

View equity

Flash note

Healthcare

05.07.24

Creo Medical — Intuitive deal expansion is a notable milestone

edison tv

Healthcare

04.06.24

Creo Medical – executive interview with Craig Gulliford, CEO

Update

Healthcare

20.05.24

USD2.15

▾ 0.09 (4.37)

As at 26/07/2024

Market capitalisation: USD57m

View equity

Flash note

Healthcare

10.07.24

Immix Biopharma — US CAR-T trial commences patient dosing

Update

Healthcare

20.05.24

Immix Biopharma — All roads lead to NEXICART-2

Update

Healthcare

03.04.24

SEK16.40

▾ −0.15 (−0.91)

As at 26/07/2024

Market capitalisation: SEK850m

View equity

edison tv

Healthcare

26.07.24

IRLAB Therapeutics – executive interview

Update

Healthcare

11.07.24

IRLAB Therapeutics — Anticipation builds as inflection points approach

Flash note

Healthcare

03.07.24

EUR1.13

▾ −0.01 (−0.88)

As at 26/07/2024

Market capitalisation: EUR34m

View equity

Mendus (IMMU)

Latest price

SEK8.10

▾ −0.15 (−1.82)

As at 26/07/2024

Market capitalisation: SEK411m

View equity

Flash note

Healthcare

24.07.24

Mendus — Collaboration unveils path forward for ilixadencel

Flash note

Healthcare

21.06.24

Mendus — Recent clinical data highlight vididencel’s potential

edison tv

Healthcare

07.06.24

USD9.42

▾ 0.70 (8.03)

As at 26/07/2024

Market capitalisation: USD678m

View equity

thematic

Healthcare

04.01.24

Outlook for 2024: Life sciences – where has the conviction gone?

edison tv

Healthcare

20.04.23

MindMed update on major depressive disorder data: Rob Barrow, CEO

edison tv

Healthcare

29.03.23

CHF8.07

▾ −0.03 (−0.37)

As at 26/07/2024

Market capitalisation: CHF154m

View equity

Flash note

Healthcare

26.06.24

Newron Pharmaceuticals — Evenamide road to registration and beyond

Flash note

Healthcare

14.05.24

Newron Pharmaceuticals — Evenamide potential for treatment of schizophrenia

Flash note

Healthcare

01.05.24

EUR0.17

▾ −0.01 (−4.44)

As at 26/07/2024

Market capitalisation: EUR12m

View equity

Flash note

Healthcare

18.12.23

Nicox — Animal data show favourable profile vs Lumigan

Update

Healthcare

14.11.23

Nicox — Q323 update confirms trajectory for NCX-470

Flash note

Healthcare

21.07.23

USD0.49

▾ 0.05 (11.62)

As at 26/07/2024

Market capitalisation: USD7m

View equity

Update

Healthcare

14.08.23

OpGen — Cash concerns dampen active Q2

Flash note

Healthcare

04.08.23

OpGen — FIND collaboration advances to development

Flash note

Healthcare

21.07.23

OpGen — Feasibility milestone from FIND collaboration

See more
content on

OpGen

Equities

Equities by Sector

Sectors

Thematics

Latest

ConsumerWatch – The times they are a-changin’

Emerging markets – Worthy of consideration

Dynam Capital at the 2024 Vietnam ESG Conference

Audiovisual

Latest

IRLAB Therapeutics – executive interview

Primary Health Properties – executive interview

Uncovering Trusts – A closer look at Emerging Markets

About Edison

About Edison

Careers

Healthcare Equities

Actinogen Medical (ACW)

AUD0.08

Actinogen Medical — Publication of XanADu biomarker analysis

Actinogen Medical — Funding in place through key catalysts

Actinogen Medical — First patient dosed in Phase IIb XanaMIA study

See morecontent on

AFT Pharmaceuticals (AFT)

NZD3.00

AFT Pharmaceuticals — Continued execution of footprint expansion

AFT Pharmaceuticals — Growth underpinned by international momentum

AFT Pharmaceuticals — Maxigesic IV’s Brazil entry, a foray into LATAM

See morecontent on

Argent Biopharma (RGT)

AUD0.31

MGC Pharmaceuticals — Rapid prescription growth in Australia and the UK

MGC Pharmaceuticals — Initial CannEpil purchase orders received

MGC Pharmaceuticals — MGC Derma sale completed

See morecontent on

Basilea Pharmaceutica (BSLN)

CHF39.30

Basilea Pharmaceutica — Final oncology asset (lisavanbulin) divested

Basilea Pharmaceutica — Cresemba milestone payments continue to roll in

Basilea Pharmaceutica — Need for innovation against severe infections

See morecontent on

Cantargia (CANTA)

SEK3.80

Cantargia — Encouraging data for nadunolimab in CANFOUR

Cantargia — First patient treated in Phase II part of TRIFOUR

Cantargia — Next phase of clinical development in sight

See morecontent on

Cereno Scientific (CRNO-B)

SEK6.10

Cereno Scientific — CS1 Phase II results inbound; first dose of CS014

Cereno Scientific — CS014 (second asset) crosses into the clinic

Cereno Scientific — All eyes on Q3 readout after Q1 update

See morecontent on

Chosa (CHOSA)

SEK0.94

Outlook for 2024: Life sciences – where has the conviction gone?

Chosa Oncology — Making headway in precision oncology

RhoVac — On the home straight

See morecontent on

Creo Medical (CREO)

GBP0.31

Creo Medical — Intuitive deal expansion is a notable milestone

Creo Medical – executive interview with Craig Gulliford, CEO

Creo Medical — Setting the stage for pivotal growth

See morecontent on

Immix Biopharma (IMMX)

USD2.15

Immix Biopharma — US CAR-T trial commences patient dosing

Immix Biopharma — All roads lead to NEXICART-2

Immix Biopharma — Reaffirmed long-term focus on outpatient CAR-T

See morecontent on

IRLAB Therapeutics (IRLAB-A)

SEK16.40

IRLAB Therapeutics – executive interview

IRLAB Therapeutics — Anticipation builds as inflection points approach

IRLAB Therapeutics — Pirepemat passes Phase IIb DSMB safety hurdle

See morecontent on

Medigene (MDG1)

EUR1.13

Mendus (IMMU)

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on